In allergy and immunology, the office visit is rarely the money — the money lives in unit counting and buy-and-bill, and Renton's payer skew makes both unforgiving. Skin and intradermal testing pays per individual test, with units set to the number of tests and held inside every plan's annual cap and medically unlikely edit; report a whole panel as one unit and you underbill by thousands a year, report over the cap and you invite a takeback. Antigen preparation is billed from the mixing log at one cc per dose, capped at ten billable doses per multidose vial for Medicare, and it is a separate service from the injection administration. The administration line is billed once per encounter for two or more injections, never multiplied, and the antigen line is billed only when your practice prepared the vial.
Biologics raise the stakes. For a severe-asthma or chronic-urticaria patient at a Renton practice, prior authorization has to be confirmed before administration, the HCPCS units have to be exact, and the discarded-drug modifier belongs on single-dose vials — three facts that decide whether a $30,000-a-year drug pays. Benefit routing shifts across Amerigroup, Community Health Plan of Washington, Coordinated Care, Molina, and UnitedHealthcare Community Plan, and Noridian carries Part B for Washington. Apple Health coverage also churns, so a patient active at one shot visit can be retroactively terminated by the next; re-verifying before every encounter is the difference between a paid series and a write-off. Modifier 25 belongs only on a distinct, documented same-day E/M — never on a routine shot — and non-covered testing such as large IgG food-sensitivity panels should be screened to an ABN rather than billed to the plan.
Renton's employer base makes the commercial side its own puzzle. Boeing and the aerospace supply chain built around it carry rich but complex plans, often with high early-year deductibles and utilization-management rules on biologics that differ from the Medicaid managed-care lanes. A patient can move between an employer plan, a spouse's plan, and a retiree Medicare Advantage product over a single treatment year, and each transition resets deductibles, prior authorizations, and benefit-routing decisions. If those changes are not caught at check-in, an immunotherapy build-up that was authorized in January can start denying in March. Getting this right is not glamorous — it is coordination-of-benefits discipline, timely-filing tracking, and payer-specific auth playbooks applied to every Renton encounter — but it is precisely where practices leave money when billing is handled off the side of a busy front desk.